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 Intra-abdominal fibromatosis (IAF) is a rare benign neoplasm arising from the abdominal fibrous
tissue, mostly in the mesentery. IAF is characterized by a tendency to infiltrate the surrounding vessels
and vital structures and recurrence after usually incomplete surgical removal. Accordingly, IAF is
associated with considerable morbidity and mortality. The authors report on a boy who presented
with a large IAF at the age of 5 years. Within 6 months after initial presentation, he underwent
4 subsequent abdominal explorations for diagnosis, tumor reduction, and intestinal obstructions.
IAF was confirmed by the presence of vimentin and absence of other biological cell markers. Due to
accelerated tumor growth and deteriorated general condition, as a last resort, a chemotherapy trial
with vincristin and methotrexate was carried out. This regimen proved to be effective in reducing
the tumor burden and improving the patient’s general condition. Outcome of IAF depends on early
diagnosis and complete tumor resection, and, if indicated, timely employment of neo/adjuvant
chemotherapy. Radiotherapy must be considered in life-threatening conditions as the last resort in a
growing child [2–4].
Keywords aggressive fibromatosis, chemotherapy, childhood, intra-abdominal
Intra-abdominal fibromatosis (IAF) is a rare tumor in children, account-
ing for less than 0.1% of all tumors (2–4 per 1,000,000 capita per year), and
affects mostly girls aged 4–5 years [1–3]. It originates from the fibrous tissue
in the mesentery or retroperitoneum and less commonly the intestinal wall
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[2, 4]. Dysregulation of β-catenin production, e.g., its elevation, may account
for the accelerated proliferation of tumor cells [5]. IAF is classified according
to its histopathological features and biological behavior as a benign tumor
with no potential for metastasis. However, it has a notable tendency to infil-
trate the adjacent structures, thus compromising vital organ functions and
vascular structures, and causing morbidity and mortality. Surgical tumor re-
section has been so far considered the first-line treatment modality for IAF
and other localized desmoid tumors. However, a complete tumor excision
is usually not feasible. Recurrence of the residual tumor (gross or micro-
scopic) is another characteristic of IAF, and a serious complication, which
might necessitate repeated surgical interventions and compromise the prog-
nosis quad vitam. Adjuvant chemotherapy is an option that must be taken
into consideration once the tumor is unresectable or takes an aggressive turn
[6–9]. Results of radiotherapy for IAF in adolescents and adults have been
variable, but it might prove beneficial in some patients [6, 10–12]. Consid-
ering the immediate and long-term side effects of of irradiation, this option
must be considered as last resort in growing young children [3, 6, 10]. Due
to the rarity of IAF in children there is only limited experience with either
therapeutic approach. The following report demonstrates the clinical course
of such a tumor and the usefulness of chemotherapy as an option in a child
with aggressive IAF.
CASE REPORT
A.H.S, a 5-year-old male, complained in March 2002 of malaise and per-
sistent abdominal pain, and presented soon after with a conspicuous mass in
the left abdominal flank. After thorough clinical investigations and imaging
procedures, including abdominal CT scan and MRI, he underwent an ex-
ploratory laparotomy. The well-vascularized tumor proved to be inoperable
due to its intra- and retroperitoneal extension and attachment to descend-
ing colon, sigmoid, part of small bowel and left renal bed, and infiltration
of the aorta, mesentery, and iliac vessels. Therefore, only careful tumor size
reduction was carried out. The histopathological study of the surgical spec-
imen indicated fibromatosis (Figure 1). This was confirmed by immunohis-
tochemical findings: positive vimentin, negative smooth muscle actin, S 100,
c-kit, and CD34. A.H.S. underwent 3 more laparotomies for recurrent tumor
growth and intestinal obstructions. The last laparotomy was carried out in
Germany in October 2002 and a short segment of proximal jejunum was re-
moved because of kinking and tumor infiltration. An attempt to reduce the
tumor mass surgically failed because of massive hemorrhage from tumoral
vessels.
After recovery, A.H.S. was sent home and referred to our department for
follow-up. At first presentation in early 2003, he was markedly dystrophic, had
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FIGURE 1 Microscopic feature of the mesenteric tumor biopsy.
a protruding abdomen with a firm tumor mass occupying the whole abdom-
inal cavity and engorged superficial abdominal wall veins. In the following
months the tumor grew and the patient’s general condition deteriorated
further. By late 2003, he complained of lassitude, anorexia, orthopnea, and
insomnia. He had developed scrotal and pretibial edema. His abdominal
circumference measured 87.5 cm and the abdominal MRI demonstrated
a huge tumor mass displacing small bowel, compressing liver and spleen
and extending into the pelvis (Figure 2). At this point, we decided to carry
out a chemotherapeutic trial. This consisted of weekly intravenous vincristin
(1.5 mg/m2) and weekly oral methotrexate (10 mg/m2). Chemotherapy was
FIGURE 2 Abdominal CT scan and MRI before chemotherapy.
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FIGURE 3 Abdominal CT scan and MRI, 9 months after chemotherapy.
commenced in early January 2004 and within a few weeks tumor shrinkage
was observed. At the same time, the patient’s general condition improved
remarkably and respiratory complaints and edema disappeared. A.H.S. now
attends elementary school and is physically active. His abdominal circum-
ference measures 60 cm 12 months after beginning of chemotherapy, and
the follow-up abdominal MRI demonstrates significant tumor shrinkage with
necrotic areas (Figure 3).
DISCUSSION
Intra-abdominal fibromatosis is a rare, benign neoplasm in children.
However, in our patient the tumor took an aggressive path, complicated by re-
current intestinal obstructions. Repeated surgical interventions were of only
temporary relief. There are few reports about the usefulness of chemother-
apy in IAF [3, 8, 9]. The decision to initiate chemotherapy in our patient was
made as the tumor expansion accelerated and the patient’s condition wors-
ened rapidly. The combination of vincristin and methotrexate proved to be
efficient and well tolerated. This regiment can be applied on an outpatient
basis and is economically affordable. Follow-up by MRI provides an opportu-
nity to monitor the tumor regression and necrosis accurately [3]. According
to current reports, there is no consensus about the duration of chemotherapy
and the necessity for maintenance therapy [3, 9] Other cytostatic drugs, such
as cyclophosphamide, actinomycin-D, doxorubicin, and vinblastin, have also
proved to be effective in controlling tumor growth. Another therapeutic op-
tion in aggressive IAF is the application of carboplatin and hyperthermia [1].
Radiotherapy will be of benefit to adolescents and adults with incompletely
resected IAF [11, 12]. There is no recommendation to apply radiotherapy in
children unless there is a life-threatening condition [3, 10]. In our patient
chemotherapy will be continued as long as tumor shrinkage continues and,
if necessary, another attempt to excise the remaining tumor tissue will be
performed.
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Clinically and therapeutically it is important to distinguish between IAF
and other childhood desmoid tumors with visceral presentation, e.g., in-
fantile myofibromatosis, juvenile fibrosarcoma, leiomyosarcoma, neurofibro-
matosis, fibromyxoid sarcoma, and gastrointestina stromal tumor. Accurate
differentiation between these rare entities can be done by refined histo-
chemical and immune marker studies [2–4] and appropriate treatment can
be initiated [13–17].
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